Pfizer identifies antiviral compounds with potential as coronavirus treatments

Pfizer has identified certain antiviral compounds it had in development that have the potential to inhibit coronaviruses and is engaging with a third party to screen the compounds.

The company said it hopes to have the results from that screening by the end of March and if any of the compounds are successful, it would hope to start testing them by the end of the year.

Mikael Dolsten, Chief Scientific Officer, Pfizer was one of a number of pharmaceutical executives who met with US President Trump at the White House recently.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.